CYPHERPUNK TECHNOLOGIES INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 2.70% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-03-26
- CYPHERPUNK TECHNOLOGIES INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 2.70%, a 68.75% increase from fiscal 2023.
- CYPHERPUNK TECHNOLOGIES INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 1.60%, a 60.00% increase from fiscal 2022.
- CYPHERPUNK TECHNOLOGIES INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was 1.00%, a 33.33% decline from fiscal 2021.
- CYPHERPUNK TECHNOLOGIES INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2021 was 1.50%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | 2.70% 10-K · filed 2025-03-26 |
| 2023-12-31 | 1.60% 10-K · filed 2025-03-26 |
| 2022-12-31 | 1.00% 10-K · filed 2024-03-18 |
| 2021-12-31 | 1.50% 10-K · filed 2023-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |